• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极光激酶A的抑制作用可限制中心体聚集,并在具有多余中心体的细胞中促进有丝分裂灾难。

Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomes.

作者信息

Navarro-Serer Bernat, Childers Eva P, Hermance Nicole M, Mercadante Dayna, Manning Amity L

机构信息

Worcester Polytechnic Institute, Department of Biology and Biotechnology, Worcester, MA, USA.

出版信息

Oncotarget. 2019 Feb 26;10(17):1649-1659. doi: 10.18632/oncotarget.26714.

DOI:10.18632/oncotarget.26714
PMID:30899434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6422193/
Abstract

The presence of supernumerary centrosomes is prevalent in cancer, where they promote the formation of transient multipolar mitotic spindles. Active clustering of supernumerary centrosomes enables the formation of a functional bipolar spindle that is competent to complete a bipolar division. Disruption of spindle pole clustering in cancer cells promotes multipolar division and generation of non-proliferative daughter cells with compromised viability. Hence molecular pathways required for spindle pole clustering in cells with supernumerary centrosomes, but dispensable in normal cells, are promising therapeutic targets. Here we demonstrate that Aurora A kinase activity is required for spindle pole clustering in cells with extra centrosomes. While cells with two centrosomes are ultimately able to build a bipolar spindle and proceed through a normal cell division in the presence of Aurora A inhibition, cells with supernumerary centrosomes form multipolar and disorganized spindles that are not competent for chromosome segregation. Instead, following a prolonged mitosis, these cells experience catastrophic divisions that result in grossly aneuploid, and non-proliferative daughter cells. Aurora A inhibition in a panel of Acute Myeloid Leukemia cancer cells has a similarly disparate impact on cells with supernumerary centrosomes, suggesting that centrosome number and spindle polarity may serve as predictive biomarkers for response to therapeutic approaches that target Aurora A kinase function.

摘要

多余中心体的存在在癌症中很普遍,它们会促进瞬时多极有丝分裂纺锤体的形成。多余中心体的主动聚集能够形成一个有功能的双极纺锤体,从而完成双极分裂。癌细胞中纺锤体极聚集的破坏会促进多极分裂,并产生活力受损的非增殖性子细胞。因此,多余中心体的细胞中纺锤体极聚集所需的分子途径,在正常细胞中并非必需,是很有前景的治疗靶点。在这里,我们证明了极光激酶A的活性是多余中心体细胞中纺锤体极聚集所必需的。虽然在有两个中心体的细胞中,在极光激酶A受到抑制的情况下最终能够构建双极纺锤体并进行正常的细胞分裂,但有多余中心体的细胞会形成多极且无序的纺锤体,无法进行染色体分离。相反,经过长时间的有丝分裂后,这些细胞会经历灾难性分裂,导致产生严重非整倍体且无增殖能力的子细胞。在一组急性髓系白血病癌细胞中抑制极光激酶A,对有多余中心体的细胞也有类似的不同影响,这表明中心体数量和纺锤体极性可能作为预测生物标志物,用于预测对靶向极光激酶A功能的治疗方法产生反应。

相似文献

1
Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomes.极光激酶A的抑制作用可限制中心体聚集,并在具有多余中心体的细胞中促进有丝分裂灾难。
Oncotarget. 2019 Feb 26;10(17):1649-1659. doi: 10.18632/oncotarget.26714.
2
Cortical dynein drives centrosome clustering in cells with centrosome amplification.皮质动力蛋白驱动具有中心体扩增的细胞中的中心体聚集。
Mol Biol Cell. 2023 May 15;34(6):ar63. doi: 10.1091/mbc.E22-07-0296. Epub 2023 Apr 5.
3
Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells.Hsp72 和 Nek6 合作在癌细胞中聚类扩增中心体。
Cancer Res. 2017 Sep 15;77(18):4785-4796. doi: 10.1158/0008-5472.CAN-16-3233. Epub 2017 Jul 18.
4
Therapeutic potential of mitotic interaction between the nucleoporin Tpr and aurora kinase A.核孔蛋白Tpr与极光激酶A之间有丝分裂相互作用的治疗潜力。
Cell Cycle. 2015;14(9):1447-58. doi: 10.1080/15384101.2015.1021518.
5
Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction.Nek2A 通过与 KIF2C 相互作用防止中心体聚集并诱导癌细胞死亡。
Cell Death Dis. 2024 Mar 16;15(3):222. doi: 10.1038/s41419-024-06601-0.
6
A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells.整联蛋白连接激酶、ch-TOG 和 TACC3 在癌细胞中心体聚集中的关键作用。
Oncogene. 2011 Feb 3;30(5):521-34. doi: 10.1038/onc.2010.431. Epub 2010 Sep 13.
7
Centrosomes and cancer: how cancer cells divide with too many centrosomes.中心体与癌症:癌细胞如何在拥有过多中心体的情况下进行分裂。
Cancer Metastasis Rev. 2009 Jun;28(1-2):85-98. doi: 10.1007/s10555-008-9163-6.
8
Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer.中心体周期失调与癌症中染色体不稳定性的起源
Adv Exp Med Biol. 2005;570:393-421. doi: 10.1007/1-4020-3764-3_14.
9
Centrosomal clustering contributes to chromosomal instability and cancer.中心体聚集会导致染色体不稳定和癌症。
Curr Opin Biotechnol. 2016 Aug;40:113-118. doi: 10.1016/j.copbio.2016.03.011. Epub 2016 Apr 2.
10
Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET.无中心体纺锤体的组织使得癌细胞依赖驱动蛋白 HSET。
J Cell Sci. 2012 Nov 15;125(Pt 22):5391-402. doi: 10.1242/jcs.107474. Epub 2012 Sep 3.

引用本文的文献

1
Transient centrosome loss in cultured prostate epithelial cells induces chromosomal instability to produce an oncogenic genotype that correlates with poor clinical outcomes.培养的前列腺上皮细胞中短暂的中心体缺失会诱导染色体不稳定,产生与不良临床结果相关的致癌基因型。
bioRxiv. 2025 May 12:2025.05.10.653266. doi: 10.1101/2025.05.10.653266.
2
Centrosome amplification primes ovarian cancer cells for apoptosis and potentiates the response to chemotherapy.中心体扩增使卵巢癌细胞对细胞凋亡敏感,并增强对化疗的反应。
PLoS Biol. 2024 Sep 5;22(9):e3002759. doi: 10.1371/journal.pbio.3002759. eCollection 2024 Sep.
3
Contribution of AurkA/TPX2 Overexpression to Chromosomal Imbalances and Cancer.

本文引用的文献

1
Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.阿利西替尼:血液系统恶性肿瘤和实体瘤患者的药代动力学、疗效及毒性综述
Expert Opin Investig Drugs. 2018 Jan;27(1):105-112. doi: 10.1080/13543784.2018.1417382. Epub 2018 Jan 3.
2
Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.极光激酶A/信号转导分子5致癌轴的分子靶向作用可恢复人乳腺癌细胞的化学敏感性。
Oncotarget. 2017 Sep 1;8(53):91803-91816. doi: 10.18632/oncotarget.20610. eCollection 2017 Oct 31.
3
Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
AurkA/TPX2 过表达对染色体失衡和癌症的贡献。
Cells. 2024 Aug 22;13(16):1397. doi: 10.3390/cells13161397.
4
Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction.Nek2A 通过与 KIF2C 相互作用防止中心体聚集并诱导癌细胞死亡。
Cell Death Dis. 2024 Mar 16;15(3):222. doi: 10.1038/s41419-024-06601-0.
5
Cortical dynein drives centrosome clustering in cells with centrosome amplification.皮质动力蛋白驱动具有中心体扩增的细胞中的中心体聚集。
Mol Biol Cell. 2023 May 15;34(6):ar63. doi: 10.1091/mbc.E22-07-0296. Epub 2023 Apr 5.
6
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.针对中心体扩增的高度侵袭性乳腺癌,靶向 TACC3 代表了一种新的脆弱性。
Cell Death Differ. 2023 May;30(5):1305-1319. doi: 10.1038/s41418-023-01140-1. Epub 2023 Mar 2.
7
Whole-Genome Duplication and Genome Instability in Cancer Cells: Double the Trouble.全基因组复制和癌细胞中的基因组不稳定性:双倍的麻烦。
Int J Mol Sci. 2023 Feb 13;24(4):3733. doi: 10.3390/ijms24043733.
8
Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights.血液系统恶性肿瘤中的中心体缺陷:分子机制与治疗见解
Blood Sci. 2022 Jul 14;4(3):143-151. doi: 10.1097/BS9.0000000000000127. eCollection 2022 Jul.
9
PEITC: A resounding molecule averts metastasis in breast cancer cells by regulating PKCδ/Aurora A interplay.萝卜硫素:一种通过调节蛋白激酶Cδ/极光激酶A相互作用来避免乳腺癌细胞转移的显著分子。
Heliyon. 2022 Nov 15;8(11):e11656. doi: 10.1016/j.heliyon.2022.e11656. eCollection 2022 Nov.
10
Modeling reveals cortical dynein-dependent fluctuations in bipolar spindle length.建模揭示了两极纺锤体长度中皮层动力蛋白依赖的波动。
Biophys J. 2021 Aug 3;120(15):3192-3210. doi: 10.1016/j.bpj.2021.05.030. Epub 2021 Jun 29.
新型抗癌 Aurora A 激酶抑制剂alisertib(MLN8237)的关键风险效益评估:临床数据的综合评价。
Crit Rev Oncol Hematol. 2017 Nov;119:59-65. doi: 10.1016/j.critrevonc.2017.09.006. Epub 2017 Sep 18.
4
Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells.Hsp72 和 Nek6 合作在癌细胞中聚类扩增中心体。
Cancer Res. 2017 Sep 15;77(18):4785-4796. doi: 10.1158/0008-5472.CAN-16-3233. Epub 2017 Jul 18.
5
Aurora kinases: novel therapy targets in cancers.极光激酶:癌症中的新型治疗靶点。
Oncotarget. 2017 Apr 4;8(14):23937-23954. doi: 10.18632/oncotarget.14893.
6
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.极光A激酶抑制剂阿利西替尼联合诱导化疗治疗急性髓系白血病患者的I期研究。
Haematologica. 2017 Apr;102(4):719-727. doi: 10.3324/haematol.2016.158394. Epub 2016 Dec 29.
7
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.靶向极光激酶治疗肺癌可减少KRAS诱导的细胞转化。
Mol Cancer. 2016 Feb 3;15:12. doi: 10.1186/s12943-016-0494-6.
8
Cross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle Assembly.有丝分裂启动和纺锤体组装过程中AURKA与Plk1之间的相互作用
Front Oncol. 2015 Dec 23;5:283. doi: 10.3389/fonc.2015.00283. eCollection 2015.
9
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.一项关于口服极光激酶A抑制剂MK-5108的I期研究,该药物作为单一疗法以及与多西他赛联合使用,用于治疗晚期或难治性实体瘤患者。
Invest New Drugs. 2016 Feb;34(1):84-95. doi: 10.1007/s10637-015-0306-7. Epub 2015 Dec 1.
10
Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.肿瘤学临床试验中的极光激酶抑制剂:进展现状
Semin Oncol. 2015 Dec;42(6):832-48. doi: 10.1053/j.seminoncol.2015.09.022. Epub 2015 Sep 24.